ClinicalTrials.gg
RecruitingNCT07189390BIPUpdated Nov 19, 2026

The Bloom Infant Probiotic (BIP) Study

A Phase 2 interventional study of Probiotic and Matching placebo in Infant, Newborn, Immunity and Immunisation, sponsored by South Australian Health and Medical Research Institute. Recruiting at 2 sites in Australia. Open to participants aged Up to 28 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by South Australian Health and Medical Research Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 19, 2026Site recruiting status changedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
Up to 28 Days
Sex
All
01

Study summary

The goal of this clinical trial is to investigate whether administering a probiotic (Infloran®) to infants who received antibiotics in the first 28 days of life can restore or enhance their immune response to routine vaccines.

Antibiotic use in the first weeks of life can lower the levels of beneficial gut bacteria, such as bifidobacteria, which play a key role in immune function. As a result, infants treated with antibiotics may produce fewer antibodies after routine vaccinations, leaving them less protected against infections.

The main questions this study aims to answer are:

  • Does treatment with the probiotic Infloran® improve the geometric mean concentrations (GMCs) of anticapsular antibodies against at least 11 serotypes included in the pneumococcal conjugate vaccine (PCV20) in serum samples collected at 6 months of age compared with placebo in infants treated with antibiotics in the neonatal period?
  • Does treatment with the probiotic Infloran® improve the GMCs for the pneumococcal conjugate vaccine (PCV20) at 12 months of age compared with placebo in infants treated with antibiotics in the neonatal period?
  • Does treatment with the probiotic Infloran® improve the GMCs of other routine childhood vaccines at 6 and 12 months of age compared with placebo in infants treated with antibiotics in the neonatal period?
  • Does treatment with the probiotic Infloran® increase the proportion of infants achieving seroprotective antibody levels for pneumococcal antigens compared to placebo in infants treated with antibiotics in the neonatal period?
  • What are the differences in antigen specific T cell responses, flow cytometry, blood transcriptomics, and gut microbiota composition in the probiotic (Infloran®) vs placebo groups in infants treated with antibiotics in the neonatal period?

Researchers will compare infants who receive Infloran® (a probiotic containing Bifidobacterium bifidum and Lactobacillus acidphilus) with those who receive a placebo (which contains the same excipients as Infloran® but does not contain any bacterial strains).

Participants will:

  • Be randomly assigned to receive either a 14-day course of probiotic Infloran® or a placebo.
  • Provide blood samples (3-5 mL) at 6 weeks, 6.5 weeks (optional blood-draw for exploratory endpoint), 6 months and 12 months of age.
  • Provide stool samples at four timepoints: prior to starting the intervention (probiotic/placebo), on day 7, on day 14 after completion of the study supplement, and prior to their first vaccination at 6 weeks of age.
  • Receive routine vaccinations at 6 weeks, 4 months and 6 months in line with the National Immunisation Program
  • Complete surveys to collect information regarding probiotic/placebo administration and vaccination related side effects

This study aims to recruit 360 infants to assess whether this probiotic treatment following antibiotic exposure improves the immunogenicity of vaccinations. The information from this study will improve our understanding of how probiotic intervention can support optimal immune responses to vaccination in early life. The findings could potentially influence public health strategies, offering a new way to support optimal vaccine responses in antibiotic-treated infants.

02

Conditions studied

  • Infant, Newborn
  • Immunity
  • Immunisation
  • Antibiotic Treatment
  • Microbiome Dysbiosis

Browse trials for

Keywords

  • infant
  • newborn
  • neonate
  • antibiotic
  • microbiome
  • microbiota
  • gut
  • probiotics
  • bifidobacteria
  • bifidobacterium
  • infloran
  • immunisation
  • immunity
  • immune system
  • vaccine
  • vaccination
  • immunization
  • randomised controlled trial
  • randomized controlled trial
03

In context

Dysbiosis

190 studies on the registry are indexed under Dysbiosis; 67 are open to participants now.

This study's planned enrollment of 360 is above the median of 60 across 134 interventional studies indexed under Dysbiosis.

Browse Dysbiosis studies →

Lead sponsor

South Australian Health and Medical Research Institute is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 28 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infants administered antibiotics in the first 28 days of life. Infants must have documented direct antibiotic exposure - defined as having received at least 36 hours of antibiotic treatment in the neonatal period (the first 28 days after birth).
  2. Gestational age ≥ 35 weeks.
  3. Birth weight ≥ 2500g.
  4. Mother aged at least 18 years and able and willing to provide written for themselves and their infant.
  5. Parent/guardian agrees to not give any other probiotics to their infant prior to vaccination at 6 weeks, including any formula that contains probiotics.
  6. Infant planning to receive all nationally approved vaccines during next 6 months.

Exclusion criteria

Exclusion Criteria:

  1. Significant medical condition in either the mother or infant that, in the opinion of a medical investigator, may interfere with the study.
  2. Infant had confirmed sepsis or other serious infection in the neonatal period.
  3. Infants with known congenital diseases or who are or considered medically at risk (MAR).
  4. Infant participating in another interventional trial during the trial period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Probiotic

    These participants will receive a probiotic, daily for fourteen days.

    Drug: Probiotic

  • Placebo comparator
    Control

    These participants will receive a placebo (contains the same excipients as the probiotic but no bacterial strains), daily for fourteen days.

    Drug: Matching placebo

Interventions

  • Probiotic capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. Probiotic Infloran® Hard capsules (Bifidobacterium bifidum \& Lactobacillus acidophilus) are a listed medicine on the Australian Register of Therapeutic Goods (ARTG). Infloran® has been previously used in infants including pre-term infants for other indications including supporting healthy digestion or improving digestive system flora. Infloran® is manufactured by Laboratorio Farmaceutico SIT S.r.l., Via Cavour 70 - 27035 Mede (PV) Italy.

    Also known as: Infloran®

  • DrugMatching placebo

    Placebo contains the same excipients as Infloran, it is also made from the same capsule, but it does not contain any bacterial strains. Placebo capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. The placebo is manufactured by Syntro Health, 558-562 Swan St, Richmond, VIC 3121.

06

What researchers measure

Primary outcomes

  1. The Geometric Mean Concentrations (GMCs) of anticapsular antibodies against at least 11 serotypes included in the pneumococcal conjugate vaccine (PCV20) in serum collected at 6 months in the probiotics vs placebo group.

    Time frame: 6 months

Secondary outcomes

  1. The GMCs for at least 11 serotypes included in pneumococcal conjugate vaccine (PCV20) as measured by serum assay at 12 months in the probiotic vs. placebo group.

    Time frame: 12 months

  2. The GMCs for other vaccine antigens (e.g. diphtheria, tetanus and pertussis toxoids, Haemophilus influenzae type b polyribosylribitol phosphate, Hepatitis B surface antigen) as measured by serum assays at 6 and 12 months in both arms.

    Time frame: 12 months

  3. Proportion of infants achieving seroprotective antibody levels (i.e. seroprotection) for pneumococcal antigens.

    Time frame: 12 months

Other outcomes

  1. Activation-induced markers (AIM) assays will be performed to assess antigen-specific CD4 and CD8 T cell responses in probiotic vs. placebo groups.

    Time frame: 12 months

  2. Flow cytometry analysis of blood samples to compare immune cell frequencies and activation marker expression in probiotic vs. placebo groups.

    Time frame: 12 months

  3. Blood transcriptomics using RNA (ribonucleic acid) sequencing to measure gene expression responses to immunisation (i.e. which genes are turned on or off in blood) in probiotic vs. placebo groups.

    Time frame: Before and after the participants' 6-week immunisations

  4. Assessment of bacterial load (qPCR (quantitative Polymerase Chain Reaction) assay) and microbial composition of the stool microbiota using metagenomics (microbial DNA sequencing) in probiotic vs. placebo groups.

    Time frame: 2 months

  5. Correlative analysis of metagenomic, transcriptomic, and immunological datasets.

    Time frame: 12 months

  6. Assessment of whether probiotic supplementation influences the incidence and severity of respiratory infections during the first 12 months of life.

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Non-identifiable individual participant data, from participants who give specific consent, may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept SAHMRI's conditions, under a collaborator agreement, for accessing: Individual participant data that underlie the results reported in our articles after deidentification (text, tables, figures and appendices) Study protocol, Statistical Analysis Plan, PICF Molecular data generated from this study (i.e. transcriptomic, epigenomic and metagenomic) will be labelled with a unique identification code and stored on an appropriate data repository (e.g. Gene Expression Omnibus, Sequence Read Archive) with demographic information (age and sex). No identifying participant information will be shared.

Supporting information: Study protocol, Informed consent form

Time frame: At the time of publication. Data will be available indefinitely.

Access criteria: Researchers from a recognised research institution can approach SAHMRI for access of data. The researcher will need to provide evidence that the proposed use of the data has been ethically reviewed and approved by an Institutional Review Board (IRB)/ Human Research Ethics Committee (HREC), and accept SAHMRI's conditions, under a collaborator agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Sep 24, 2025
StartActual
May 25, 2026
Primary completionEst.
May 2029
CompletionEst.
Oct 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Flinders Medical Centre is now Recruiting
Nov 19, 2026
Sponsor
Collaborators added: Southern Adelaide Local Health Network·Women's and Children's Hospital, Australia; collaborators removed: Women's and Children's Hospital, Adelaide·Flinders Medical Center·Women's & Children's Hospital Foundation
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Flinders Medical Centre is now Recruiting
    Sponsor Collaborators added: Southern Adelaide Local Health Network·Women's and Children's Hospital, Australia; collaborators removed: Women's and Children's Hospital, Adelaide·Flinders Medical Center·Women's & Children's Hospital Foundation
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07189390
Lead sponsor
South Australian Health and Medical Research Institute
Collaborators
Flinders University, The University of Western Australia, Southern Adelaide Local Health Network, Women's and Children's Hospital, Australia
Responsible party
David Lynn (Professor, South Australian Health and Medical Research Institute) — Principal investigator
First posted
Sep 24, 2025
Start date
May 25, 2026
Primary completion
May 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

David Lynn
Contact
david.lynn@sahmri.com
+61 881 284 053
Elisabeth Reid
Contact
elisabeth.reid@sahmri.com
+61 881 284 247

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion